Pre-order interest now open
Line up early access to HEXA six-organ chest CT analysis
HEXA is an AI screening-support tool from Xcube. Nalin MedTech is collecting pre-order interest from screening centres, hospitals, imaging groups, and distributors who want to line up early access ahead of European commercial availability.
Pre-order interest is non-binding and subject to regulatory status, final commercial terms, and territory availability. The goal is to identify qualified partners early so Nalin can prioritise demonstrations, documentation, and allocation discussions.
Watch the HEXA overview
The short manufacturer video shows the six-organ analysis workflow and reporting interface. It is the fastest way for a procurement or clinical team to judge whether HEXA belongs in your preorder pipeline.
In plain English
Most chest CT screening workflows focus mainly on the lungs. HEXA looks for additional signals across five more organ areas, then helps organise those findings so a physician can review them faster and explain them more clearly.
It does not replace a radiologist or physician. It gives screening teams another layer of structured analysis to support review, follow-up decisions, and patient communication.
What HEXA reviews
- Lung
- Heart
- Liver
- Thyroid
- Spine
- Breast
- Cardiac calcification
- Calcified lung mass
- Focal breast calcification
- Focal thyroid hypertrophy
- Focal liver lesion
- Osteoporotic calcification
How the workflow works
- Import CT data from the screening workflow, automatically or manually.
- Segment tissue and organ areas using Hounsfield Unit values and AI models.
- Highlight abnormal areas such as calcifications, lesions, nodules, and organ-specific findings.
- Generate a structured report with locations, measurements, and relevant screenshots.
- Support physician review for final interpretation and clinical decision-making.
Performance at a glance
96.20%
Manufacturer materials report third-party Korea Testing Laboratory results for localised and calcified lesion detection across six organs, with an average positive predictive value of 96.20%.
| Organ | Reported PPV |
|---|---|
| Lung | 99.56% |
| Liver | 98.82% |
| Thyroid gland | 90.36% |
| Spine / backbone | 98.38% |
| Breast | 92.59% |
| Heart | 97.48% |
| Average | 96.20% |
Source note: performance figures are taken from manufacturer materials referencing Korea Testing Laboratory results. They should be reviewed as part of clinical, regulatory, and procurement due diligence.
Why screening centres care
Common questions
What is HEXA?
HEXA is AI chest CT analysis software from Xcube that reviews one chest CT across six organs and generates structured findings for physician review.
Which organs does HEXA analyze?
HEXA analyzes the lungs, heart, liver, thyroid, spine, and breast from a single chest CT.
Does HEXA replace a radiologist?
No. HEXA is a screening-support and reporting tool. Physician review and clinical judgment remain required for final interpretation and diagnosis.
Who should consider HEXA?
HEXA is most relevant for health screening centres, hospitals, imaging groups, diagnostic platforms, and medical-technology distributors interested in AI-enhanced chest CT screening.
Is HEXA available in Europe?
CE marking under the EU MDR is in progress. Until CE marking is complete, HEXA is not available for sale within the EU/EEA.
Can we pre-order HEXA?
You can register pre-order interest with Nalin MedTech. This is an early commercial enquiry, not a completed sale, and remains subject to regulatory status, territory availability, allocation, and final terms.
Regulatory notice. HEXA is developed by Xcube in the Republic of Korea. CE marking under the EU Medical Device Regulation (2017/745) is in progress; HEXA is not yet available for sale within the EU/EEA. Pre-order interest is a non-binding commercial enquiry and does not constitute an offer for sale. Korean licensing, patent, and KTL performance references apply to their respective jurisdictions and source materials. HEXA supports screening and physician review; it does not replace clinical judgment.